NervGen Pharma Corp (NGENF)

[Schekin]

I think it will. But… WTFDIK? I’ve listened to all of the interviews. This is currently the latest

. The human Spinal Cord injury trials are ongoing now. They have projected results being published around June. The action in the stock rise may be a result of positive results leaking from the phase 2b trials. The drug is called NVG-291. It’s a peptide that was developed and has shown to affect scar tissue thereby allowing the spinal cord to continue healing/regenerating. It doesn’t really “reverse” nerve damage. It allows the nerves to regenerate which the scar tissue prevents. I’m confident there will be positive results in the human spinal cord injury trial but what really excites me is the potential for studies which will come fairly quickly after positive results. The later trials will be for efficacy in MS and then Alzheimer’s among other nerve disorders. The interview withe the developer posted above explains better than I can. Only 59. Million shares and I believe most people purchasing the stock now know the potential here. There’s very little selling.
Also, the Chief Medical Officer is a guy who came from Amgen. https://nervgen.com/management/